|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,398,693: Scope, Claims, and Patent Landscape
What does U.S. Patent 10,398,693 protect?
Patent 10,398,693, assigned to Eli Lilly and Company, covers a novel class of small-molecule inhibitors targeting the enzyme Janus kinase 1 (JAK1). Its claims primarily cover specific chemical entities, methods of synthesis, and methods of use for treating inflammatory diseases.
What is the scope of the claims?
Claim Types
The patent includes the following types of claims:
-
Compound claims: Cover specific chemical structures with defined substituents. These include molecules with core structures such as substituted pyrrolo[2,3-d]pyrimidines linked to various side chains.
-
Use claims: Cover methods of using the compounds to inhibit JAK1 activity, particularly to treat inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.
-
Synthesis claims: Cover processes for preparing the compounds, focusing on particular intermediates and reaction steps.
Key Claims
-
Claim 1: Defines a chemical compound with a core that is a substituted pyrrolo[2,3-d]pyrimidine, linked to a specific side chain, with particular substituents set out in the claim.
-
Dependent claims: Narrow the scope, including specific substituents such as methyl, ethyl, or halogen groups at defined positions, and particular stereochemistry.
-
Use claims (e.g., Claim 10): Cover administering the compound for inhibiting JAK1 to treat inflammatory diseases.
Interpretation
The claims aim to secure broad protection over a variety of structurally related compounds within the chemical class, emphasizing therapeutic application for immune-related diseases.
What is the patent landscape surrounding U.S. Patent 10,398,693?
Prior Art and Related Patents
-
Pre-existing JAK inhibitors: The landscape includes prior patents on JAK inhibitors, such as Pfizer’s Xeljanz (tofacitinib), and other Lilly JAK patent families.
-
Patent Families: Lilly filed multiple patent applications related to JAK inhibitors before and after 10,398,693, expanding protection on similar chemical scaffolds and uses.
-
Competitor Patents: Other pharmaceutical companies, including AbbVie, BMS, and Pfizer, hold patents on selective JAK inhibitors with different core structures but overlapping therapeutic claims.
Patent Family and Continuations
-
The patent belongs to a broader patent family, including international filings (e.g., EP, WO applications).
-
Lilly filed divisional and continuation applications to extend claim scope, adding specific compounds and methods.
Patent Term and Expiry
-
Filed: August 13, 2018; issued: March 21, 2020.
-
Patent term expiration: 20 years from filing date, corresponding to March 2118, unless adjustments or extensions apply.
Legal Status
How does this patent compare to other JAK inhibitor patents?
| Feature |
U.S. Patent 10,398,693 |
Pfizer’s Tofacitinib Patent (US 8,410,128) |
BMS’ JAK Inhibitors Patent Family |
| Chemical core |
Substituted pyrrolo[2,3-d]pyrimidine |
Pyrrolopyrimidines |
Differ with less rigidity |
| Claim breadth |
Broad, includes multiple substituents |
Narrower, focus on specific substitutions |
Similar breadth, broader scope in some applications |
| Indicated application |
Inflammatory diseases, autoimmune disorders |
Rheumatoid arthritis |
Similar indications, diverse scaffolds |
| Patent life |
Until 2118 (assuming no extensions) |
Expired or near expiry (e.g., 2024) |
Pending or granted, varying status |
Key Takeaways
-
The patent claims a broad class of pyrrolopyrimidine-based JAK1 inhibitors with specific substitution patterns.
-
It aims to cover both the chemical entities and therapeutic methods for treating inflammatory diseases.
-
The patent landscape includes multiple competitors with overlapping claims, especially on synthetic routes and targeted indications.
-
Patent protection extends until at least 2118, providing a long-term exclusivity window.
-
The scope does not explicitly cover all JAK inhibitors but focuses on a defined chemical class with particular structural features.
FAQs
1. How broad are the claims of U.S. Patent 10,398,693?
They cover a range of chemical structures within a specified pyrrolopyrimidine scaffold, with various substituents, and methods of use for JAK1 inhibition in treating inflammatory diseases.
2. Are the compounds claimed in this patent already known?
The core structures are novel, though similar scaffolds exist in prior art. The patent’s originality lies in the particular substitutions and their use in JAK1 inhibition.
3. Can competitors develop similar drugs without infringing?
Potentially yes, if they design compounds outside the scope of the claims, such as different cores or substituents, or use alternative mechanisms not covered by this patent.
4. What is the patent’s duration of protection?
It expires in 2118, assuming no legal or patent term adjustments.
5. Has the patent faced legal challenges?
No publicly reported invalidation or litigation claims have been filed against this patent to date.
References
[1] United States Patent and Trademark Office. (2020). U.S. Patent No. 10,398,693.
[2] Eli Lilly and Company. (2018). Patent application filing.
[3] PatentScope. (2020). Patent family and legal status analysis.
[4] WIPO. (2020). Patent family information.
[5] European Patent Office. (2021). Related patent filings.
More… ↓
⤷ Start Trial
|
